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Abstract
Abdominal aortic aneurysm (AAA) is an inﬂammatory vascular disease characterized by structural deterioration of the
aorta caused by inﬂammation and oxidative stress, leading to aortic dilatation and rupture. Peroxiredoxin 2 (PRDX2), an
antioxidant enzyme, has been reported as a potential negative regulator of inﬂammatory vascular diseases, and it has
been identiﬁed as a protein that is increased in patients with ruptured AAA compared to patients with nonruptured
AAA. In this study, we demonstrated that PRDX2 was a pivotal factor involved in the inhibition of AAA progression.
PRDX2 levels were increased in AAA compared with those in normal aortas in both humans and mice. Ultrasound
imaging revealed that the loss of PRDX2 accelerated the development of AAA in the early stages and increased AAA
incidence in mice infused with angiotensin II (Ang II). Prdx2−/− mice infused with Ang II exhibited increased aortic
dilatation and maximal aortic diameter without a change in blood pressure. Structural deterioration of the aortas from
Prdx2−/− mice infused with Ang II was associated with increases in the degradation of elastin, oxidative stress, and
intramural thrombi caused by microhemorrhages, immature neovessels, and the activation of matrix metalloproteinases
compared to that observed in controls. Moreover, an increase in inﬂammatory responses, including the production of
cell adhesion molecules and the accumulation of inﬂammatory cells and proinﬂammatory cytokines due to PRDX2
deﬁciency, accelerated Ang II-induced AAA progression. Our data conﬁrm that PRDX2 plays a role as a negative
regulator of the pathological process of AAA and suggest that increasing PRDX2 activity may be a novel strategy for the
prevention and treatment of AAA.

Introduction
Abdominal aortic aneurysm (AAA) is an aortic disorder
with a prevalence of 2 to 8% in men older than 65 years. If
rupture occurs, AAA has a mortality rate that has been
reported to be between 85 and 90%1,2. Degradation of the
elastic media, activation of various proteases, inﬁltration
of inﬂammatory cells, increased production of cytokines
and formation of neovessels are closely linked to the
development of AAA3. Oxidative stress caused by reactive
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oxygen species (ROS) generation during inﬂammatory
processes involved in the pathogenesis of AAA induces
the activation of matrix metalloproteinases (MMPs) and
proteolytic degradation of structural proteins4. Evidence
of increased oxidative stress in tissue samples from
patients with AAA implicates ROS in the pathogenesis of
AAA5–7. Genetic and pharmacological inhibition of oxidative stress attenuates aneurysmal aortic diseases in
animal models8,9. Despite our advanced understanding of
AAA pathology, surgical management, including open
surgery and endovascular repair, is currently the only
proven effective intervention because of the lack of
pharmacological
agents3,10.
Angiotensin-converting
enzyme inhibitors and β blockers have failed to inhibit
aneurysm expansion in clinical trials11–13. It is necessary
to clarify the effects of statins, tetracycline, and macrolides
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on the progression of aneurysmal disease14–18. Thus,
novel candidates for the regulation of AAA progression
are needed for the development of pharmacological
agents with favorable safety proﬁles.
Peroxiredoxins (PRDX) are a ubiquitous family of thiolspeciﬁc antioxidant enzymes that control the levels of
intracellular peroxide, which is involved in oxidative stress
and signal transduction19–21. In mammalian cells, the
PRDX family includes six isoforms (PRDX1–PRDX6),
which are distributed in various intracellular compartments22. PRDX1 and PRDX2 are the most abundant proteins among these six isoforms and exhibit high afﬁnity for
hydrogen peroxide at low concentrations in the cytosol of
cells23. Recently, we demonstrated the anti-atherogenic
roles of PRDX1 and PRDX2 in apolipoprotein E-deﬁcient
(ApoE−/−) mice in a speciﬁc manner24,25. PRDX1 plays an
important role in lipophagic ﬂux and maintains cholesterol
homeostasis in macrophages in the presence of oxidative
stress, leading to a decrease in the formation of foam cells
and atherosclerotic plaques24. Deﬁciency of PRDX2 in
ApoE−/− mice enhanced the activation of p65, c-Jun, c-Jun
N-terminal kinases, and p38 mitogen-activated protein
kinase, accelerating the formation of atherosclerotic plaques25. PRDX2 deﬁciency in ApoE−/− mice increased the
expression of cell adhesion molecules (CAM) on vascular
endothelial cells, which was followed by an increase in
immune cell inﬁltration into the plaque25. Moreover, Choi
et al.26 reported that PRDX2 negatively regulated plateletderived growth factor (PDGF) receptor signaling and subsequently suppressed the proliferation and migration of
vascular smooth muscle cells (VSMCs). In a study comparing the proteomic composition of aneurysmal aortas in
patients with nonruptured aneurysms and those with ruptured aneurysms, higher levels of PRDX2 were revealed in
patients with ruptured AAAs than in those with nonruptured AAAs27. However, the potential role of PRDX2 in
the progression of AAA has not been explored. In this
study, we revealed that PRDX2 inhibits the angiotensin II
(Ang II)-induced formation of AAA by reducing oxidative
stress and inﬂammatory responses in aortic lesions and
preventing structural damage to the aorta.

Materials and methods
Human tissue studies

AAA tissue samples were obtained from patients during
surgical repair of the aneurysmal aorta. Normal aortic
tissues were obtained from the abdominal arteries of
patients with end-stage renal disease during kidney
transplantation. The samples were harvested from
patients who underwent surgery at Severance Hospital,
Yonsei University (Seoul, Republic of Korea). All patients
provided written informed consent. To ensure the strict
protection of privacy, identifying information was
removed from all samples before analysis. This study
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conformed to the principles outlined in the Declaration of
Helsinki and was approved by the Institutional Review
Board of Severance Hospital (IRB No. 4-2013-0688).
Generation of the mouse AAA model and animal studies

The Prdx2+/+ and Prdx2−/− mice were derived from
C57BL/6J congenic lines that were backcrossed more than
10 times with C57BL/6J mice. Mice were housed in polycarbonate cages (ﬁve per cage) under speciﬁc pathogenfree conditions and maintained under a 12-h light/dark
cycle at 22–23 °C with ad libitum access to water. All
studies were performed in accordance with the Guidelines
on the Care and Use of Laboratory Animals (National
Institutes of Health Publication no. 85–23, revised 1996)
and were approved by the Institutional Animal Care and
Usage Committee (IACUC No. 2012-01-052) of Ewha
Womans University (Seoul, Republic of Korea). The formation of an aneurysm in the mouse model was induced
through infusion of Ang II. Brieﬂy, saline or Ang II was
infused into 8-week-old mice via subcutaneous osmotic
pumps at 1000 ng/kg/min for a maximum of 4 weeks. After
the study, all animals were anesthetized by inhalation of
isoﬂurane (3%) plus 1 L/min O2 and euthanized by
exsanguination. The severity of the aneurysm (stage 0–4)
was classiﬁed as previously described28.
Ultrasound in vivo imaging

Echocardiography was performed under anesthesia
through inhalation of 1.5–2% isoﬂurane (Forene isoﬂurane; Abbott Scandinavia AB, Kista, Sweden). Images
were captured using the Vevo 2100 system (version 1.5.0;
Visual Sonics, Toronto, ON, Canada) with a 30-MHz
linear transducer. The maximal internal diameters of the
aortic images were measured using VEVO 2100 software.
Blood pressure

Blood pressure (BP) was measured using a noninvasive
tail–cuff system (CODA-HT4; Kent Scientiﬁc Corporation,
Torrington, CT). Brieﬂy, mice were acclimated to BP
measurement conditions on a daily basis for 1 week. After
acclimation, BP was measured two times, once before and
once after the implantation of the Ang II pumps, to
determine the basal and Ang II-induced BP values in each
mouse cohort. For the BP measurements, we placed the
mice in tail–cuff restraints on a warmed surface (39 °C).
Histological and immunoﬂuorescence staining

For histological examination, hematoxylin and eosin
(H&E) staining, and Movat pentachrome staining were
performed. Anti-CD31 (MAB1398Z; Millipore, Burlington, MA), anti-alpha-smooth muscle actin (anti-α-SMA;
A5228; Sigma-Aldrich, St. Louis, MO; and ab5694; Abcam,
Cambridge, United Kingdom), anti-CD45 (Mab114; R&D
Systems, Minneapolis, MN), anti-PRDX2 (ab109367;
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Abcam), anti-4-hydroxynonenal (anti-4-HNE; ab46545;
Abcam), anti-DNA/RNA damage antibody (anti-8-OHG)
(ab62623; Abcam), and anti-mouse macrophage/monocyte
antibody (anti-MOMA2) (MCA519G; Bio-Rad, Hercules,
CA) were used as primary antibodies for immunostaining.
After incubation with the primary antibodies, Alexa 488
and 594 (Invitrogen, Carlsbad, CA) or biotinylated secondary antibodies with 3,3′-diaminobenzidine substrate
(Vector Laboratories, Burlingame, CA) were used to
visualize the antigens. Furthermore, 4′,6-diamidino-2phenylindole (DAPI) or hematoxylin was used to label the
nuclei. The negative control tissues were prepared in a
similar manner using IgG isotype control antibodies
(Santa Cruz Biotechnology, Dallas, TX). The immunoﬂuorescence was imaged with an LSM 510 meta confocal
microscope (Carl Zeiss, Oberkochen, Germany) or a BX53
microscope (Olympus, Tokyo, Japan).
In situ zymography

We performed in situ zymography to evaluate the
activity of MMP in atherosclerotic plaques. Freshly cut
cryosections (10 μm thick) of the aortic sinus were incubated with a green ﬂuorogenic gelatin substrate (DQ
gelatin; Molecular Probes) according to the protocol
provided by the manufacturer. MMP-mediated proteolysis was detected with an LSM 510 meta confocal
microscope (Carl Zeiss), and MMP activity was measured
using ZEN software (Carl Zeiss).
In situ detection of ROS

Dihydroethidine (DHE) was used to visualize the production of superoxide. Brieﬂy, aortic tissues (10 μm thick)
were obtained from Prdx2+/+ and Prdx2−/− mice infused
with Ang II. Cross-sections of aortic tissues were incubated with DHE (10 μmol/L dissolved in dimethyl sulfoxide) in a light-protected humidiﬁed chamber at 37 °C
for 15 min. The sections were not washed and were
directly visualized using ﬂuorescence microscopy (LSM
510 meta confocal microscope; Carl Zeiss).
Isolation of mouse aortic VSMCs

Mouse aortic VSMCs were isolated from male mice
(20–25 g) and maintained in Dulbecco’s modiﬁed Eagle
medium containing 10% fetal bovine serum at 37 °C in a
humidiﬁed atmosphere of 5% CO2 and 95% air, as
described previously29. VSMCs were passaged four to six
times at 70–80% conﬂuence. Cells were treated with Ang
II (100 nM) for 24 or 48 h.
Immunoblotting and enzyme-linked immunosorbent assay

For the isolation of proteins, samples were lysed in
radioimmunoprecipitation assay buffer (50 mM Trishydrochloride [pH 7.4], 150 mM sodium chloride, 0.1%
sodium dodecyl sulfate, 1% NP-40, 0.25% sodium
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology
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deoxycholate, 1 mM ethylenediaminetetraacetic acid,
1 mM sodium ﬂuoride, and 1 mM sodium orthovanadate) and protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). For the western blotting
analysis, proteins were electrophoresed on 10% sodium
dodecyl sulfate-polyacrylamide gels and transferred
onto polyvinylidene diﬂuoride membranes. The membranes were blocked with 4% skim milk in Tris-buffered
saline containing 0.5% Tween-20. They were subsequently incubated with anti-PRDX2 (ab109367; Abcam),
anti-β-actin (Abc-2004; Abclon, South Korea), antiglyceraldehyde-3-phosphate
dehydrogenase
(antiGAPDH; Santa Cruz Biotechnology), anti-hemoglobin
(LS-BIO, LS-B12169), anti-vascular endothelial cadherin
(anti-VE-Cadherin; AF1002; R&D Systems), antivascular endothelial growth factor receptor 2 (antiVEGFR2; 9698; Cell Signaling Technology, Danvers,
MA), anti-α-SMA (ab5694; Abcam), anti-MMP2
(AF1488; R&D Systems), anti-MMP9 (AF909; R&D
Systems), anti-ﬁbronectin (ab2413; Abcam), anticollagen IV (ab6586; Abcam), anti-4-HNE (ab46545;
Abcam), anti-intercellular adhesion molecule-1 (antiICAM-1; AF796; R&D Systems), anti-vascular CAM-1
(anti-VCAM-1; AF643; R&D Systems), and anti-CD45
(AF114; R&D Systems) primary antibodies. This was
followed by incubation with horseradish peroxidaseconjugated secondary antibody (IgG). The immunoreactive bands were detected through enhanced chemiluminescence (Amersham). For the sandwich enzymelinked immunosorbent assay, Duoset Ab pairs detecting
interleukin (IL)-1β (DY401) and IL-6 (DY406) were
purchased from R&D Systems.
Two-dimensional gel electrophoresis and protein
identiﬁcation using matrix‐assisted laser
desorption–ionization time of ﬂight

A protein sample (1 mg) from each group (n = 3
pooled) was loaded and subjected to two-dimensional
(2D) gel electrophoresis. The gels were stained with
Coomassie dye and scanned using a photo scanner. The
comparative analysis for the relative quantiﬁcation of
samples was performed using ImageMaster 2D Platinum7
(GE Healthcare, Waukesha, WI) to determine the differential expression of the proteins according to the protein
spots. The mass of the dried peptide mix was analyzed
using matrix-assisted laser desorption–ionization time-ofﬂight (MALDI‐TOF) mass spectrometry (ULTRAFLEX
III; Bruker Daltonics, Billerica, MA). After digestion with
trypsin, the dried peptide mix was resuspended in Tris
acetate buffer and then mixed with α‐cyano‐4‐hydroxycinnamic acid (α‐CHCA, MW189.04 Da) matrix (sample-to-matrix ratio: 1:10). The resulting 2 µl sample was
spotted onto the MALDI target plate. Further analysis was
conducted using Flex Analysis software (Bruker) to obtain
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the peptide mass ﬁngerprint of the individual peptide
fragments. The resulting peptide masses were submitted
to the MASCOT server (version 2.1; Matrix Science,
Boston, MA).
Statistical analysis

Values are expressed as percentages or the means ±
standard error of the mean, as appropriate. The statistical
tests included the two‐tailed Student’s t test, one-way
analysis of variance and the Mann–Whitney U statistical
test. P values <0.05 denoted statistical signiﬁcance.

Results
Aneurysmal lesions increase the levels of PRDX2 in the
aortas of humans and mice

Our approach was based on the signiﬁcant changes in
the composition of aneurysmal aortic tissues, which were
characterized by intraluminal thrombus, immune cell
inﬁltration, and alteration of VSMCs. We initially examined the expression of PRDX2 through immunoblotting
analysis in normal or aneurysmal aortas from human
patients and mice. Aneurysmal aortic lesions from
patients with AAA expressed signiﬁcantly higher levels of
PRDX2 than those from normal controls (Fig. 1a, b). After
infusion of saline or Ang II in 8-week-old C57BL/6 male
mice for 4 weeks via subcutaneous implantation of
osmotic pumps, we isolated the suprarenal arteries,
including normal aortas from saline-infused mice, nonAAA from Ang II-infused mice and AAA from Ang IIinfused mice. The levels of PRDX2 were found to have
increased dramatically in AAA from the Ang II group
compared with those in normal aortas from the saline
group or non-AAA from the Ang II group (Fig. 1c, d).
Moreover, non-AAA from the Ang II group showed signiﬁcantly higher expression of PRDX2 than normal aortas
from the saline group (Fig. 1c, d). These results indicate
that PRDX2 expression is closely linked to the development of AAA, suggesting the potential role of PRDX2 in
AAA pathology in both humans and mice.
To explore the cellular localization of PRDX2 in AAA,
we stained PRDX2 with CD31 to identify endothelial cells
(ECs), α-SMA to identify VSMCs or CD45 to identify
immune cells in AAA lesions. PRDX2 colocalized with
markers of ECs, VSMCs, and immune cells in AAA
lesions, but the levels of PRDX2 were higher in VSMCs
than in other types of cells in AAA (Fig. 1e). Treatment of
isolated primary VSMCs with Ang II slightly increased the
expression of PRDX2 on day 2 and stimulated the release
of PRDX2 into the media (Fig. 1f). Therefore, we tested
whether the levels of PRDX2 could be detected in plasma
from mice infused with saline or Ang II and whether they
changed during the progression of AAA. The levels of
PRDX2 in plasma were detected in both groups (Fig. 1g).
As PRDX2 is one of the primary antioxidants in red blood
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology
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cells (RBCs), we normalized the levels of PRDX2 in
plasma according to the hemoglobin level. To evaluate the
correlation between PRDX2/hemoglobin levels in plasma
and the maximum suprarenal aortic diameter, we generated a scatter plot and determined the coefﬁcient of
determination. The coefﬁcient of determination showed
no signiﬁcant correlation between the two factors (Fig. 1h
and Supplementary Fig. 1).
PRDX2 deﬁciency increases AAA incidence and aortic
dilatation by Ang II

To rule out the inﬂuence of other pathological factors,
including hyperlipidemia and atherogenesis, on the progression of AAA, we used C57BL/6 background mice to
evaluate the effect of PRDX2 on the development of AAA.
Prdx2+/+ and Prdx2−/− male mice were subcutaneously
infused with saline (n = 15–20) or Ang II (n = 37) for
4 weeks using osmotic pumps to determine the potential
role of PRDX2 in the pathology of AAA. The development
of AAA in mice was tracked using serial transabdominal
ultrasound imaging. We found that the incidence of AAA
was markedly different between Prdx2+/+ and Prdx2−/−
mice during Ang II infusion. Prdx2−/− mice showed an
increase in the incidence of AAA from 24% in week 1 to 40%
in week 4. Prdx2+/+ mice showed an increase in the incidence of AAA from 5% in week 1 to 13% in week 4 (Fig. 2a).
Ultrasound imaging in B-mode of the forward long and
short axes revealed that the maximal intraluminal diameters
in the suprarenal regions of the abdominal aorta were not
different between Prdx2+/+ and Prdx2−/− mice infused with
saline. However, the loss of PRDX2 signiﬁcantly increased
the maximal intraluminal diameter in aortas from mice
infused with Ang II in week 3 (Fig. 2b–d). In addition to
increased aortic dilatation, we identiﬁed an increase in turbulent blood ﬂow in the suprarenal regions of the abdominal
aorta in Prdx2−/− mice infused with Ang II compared with
that in controls using color and pulsed wave Doppler
(Fig. 2e). However, the two groups infused with saline
showed normal blood ﬂow in the suprarenal regions of the
aorta (Supplementary Fig. 2).
Loss of PRDX2 exacerbates Ang II-induced AAA without a
change in BP

An increase in BP is a risk factor for the formation of
AAA3. Therefore, we tested the BP of mice in four groups
using a noninvasive tail–cuff system. Infusion of Ang II in
week 2 increased the systolic and diastolic BP in both
groups compared with the BP values obtained before
treatment. However, the loss of PRDX2 did not affect the
susceptibility to Ang II-mediated alteration of BP (Fig. 3a,
b). After 4 weeks, whole aortas from Prdx2+/+ and
Prdx2−/− mice infused with saline or Ang II were isolated
and evaluated. Macroscopic images showed an increase in
severe structural damage, including tortuous morphology
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Fig. 1 PRDX2 is increased in the aneurysmal aortas of humans and mice. a Immunoblotting analysis and b quantiﬁcation of PRDX2 in healthy
and aneurysmal aortas obtained from patients (n = 3). Data are presented as the mean ± SEM (two‐tailed Student’s t test). c Immunoblotting analysis
and d quantiﬁcation of PRDX2 in abdominal aortas obtained from C57BL/6 mice infused with saline (non-AAA) and Ang II (non-AAA and AAA; n = 3).
Data are presented as the mean ± SEM (one-way ANOVA). e Representative immunostaining images of PRDX2 (green) with CD31 (red, left), α-SMA
(red, middle), or CD45 (red, right) on AAA. Cross-sectional low magniﬁcation images (top; scale bar, 200 µm) with higher magniﬁcation of the boxed
area (lines 2–4; scale bar, 100 µm). Nuclei were stained with DAPI. f Immunoblotting analysis of PRDX2 in total cell lysates and concentrated culture
media of primary VSMCs isolated from Prdx2+/+ and Prdx2−/− mice. Ang II was administered to primary VSMCs during the indicated times.
g Immunoblotting analysis of PRDX2 in plasma from mice infused with saline or Ang II. Hemoglobin was used for the normalization of PRDX2 levels
in plasma obtained from RBC lysis. Ponceau S staining was used as a loading control. h Scatter plot and coefﬁcient of determination between PRDX2/
hemoglobin in mouse plasma and the maximum suprarenal aortic diameter of mice infused saline or Ang II.
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Fig. 2 Loss of PRDX2 increases AAA incidence and aortic dilatation by Ang II. a The incidence of AAA (%) was evaluated using ultrasound
imaging for 4 weeks in Prdx2+/+ and Prdx2−/− mice infused with Ang II (n = 37). b Representative ultrasound imaging of the long axis and c the short
axis of the suprarenal regions of Prdx2+/+ and Prdx2−/− mice infused with saline or Ang II. d Quantiﬁcation of the maximal intraluminal aortic
diameter of the suprarenal regions from Prdx2+/+ and Prdx2−/− mice infused with saline (n = 15–20) or Ang II (n = 37) by ultrasound imaging. Data
are presented as the mean ± SEM (two‐tailed Student’s t test). e Representative ultrasound images of the long axis obtained from color Doppler (top)
and pulse wave (bottom) mode in the suprarenal regions of Prdx2+/+ and Prdx2−/− mice infused with Ang II.

and intramural thrombi, in the aortas of Prdx2−/− mice
infused with Ang II compared with that in aortas of
Prdx2+/+ mice infused with Ang II (Fig. 3c). Moreover,
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology

the maximal aortic diameters in the suprarenal, ascending, and thoracic aortic regions were signiﬁcantly enlarged
in Prdx2−/− mice infused with Ang II compared with
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Fig. 3 Deﬁciency of PRDX2 exacerbates Ang II-induced AAA without a change in blood pressure. a Systolic blood pressure in Prdx2+/+ and
Prdx2−/− mice infused with saline (n = 4–6) or Ang II (n = 17–18) at weeks 0 and 2. b Diastolic blood pressure in Prdx2+/+ and Prdx2−/− mice infused
with saline (n = 4–6) or Ang II (n = 17–18) at weeks 0 and 2. *P < 0.05 vs before infusion (two‐tailed Student’s t test for a and b). c Representative
macroscopic images of whole aortas from Prdx2+/+ and Prdx2−/− mice infused with saline or Ang II for 4 weeks. d Quantiﬁcation of the maximal
suprarenal aortic diameter, e the maximal ascending aortic diameter, and f the maximal thoracic aortic diameter in Prdx2+/+ and Prdx2−/− mice
infused with saline (n = 5–8) or Ang II (n = 20) for 4 weeks. All data are presented as the mean ± SEM (nonparametric Mann–Whitney U test for d–f).

those in Prdx2+/+ mice infused with Ang II. However,
there was no difference between Prdx2+/+ and Prdx2−/−
mice infused with saline (Fig. 3d–f).
Loss of PRDX2 disrupts the structural integrity of aortas in
Ang II-induced AAA

Subsequently, we evaluated the severity of AAA by
characterizing the abdominal aortic lesions. According to
Daugherty’s classiﬁcation of AAA28, the abdominal aortic
lesions of Prdx2+/+ and Prdx2−/− mice infused with Ang
II were classiﬁed from 0 (no aneurysm) to 4 (multiple
aneurysms with thrombi) using macroscopic images and
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology

histological analysis with H&E and Movat pentachrome
staining of aortic cross-sections. After cross-sectional
dissection of AAA regions, we found increased dilatation
and severe structural disruption in the abdominal aortic
lesions of Prdx2−/− mice infused with Ang II compared
with those of controls (Fig. 4a). Additionally, Ang IIinduced degradation of the elastic lamina in the suprarenal
artery was signiﬁcantly increased in PRDX2-deﬁcient mice
versus that in controls, whereas there was no difference in
the groups infused with saline (Fig. 4b, e and Supplementary Fig. 3a). Using α-SMA immunostaining, we
identiﬁed that the expansion of VSMCs in the aneurysmal
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Fig. 4 Loss of PRDX2 accelerates the structural deterioration of aortas in mice with Ang II-induced AAA. a Representative H&E- and b Movat
pentachrome-stained images of cross-sectioned abdominal aortas from Prdx2+/+ and Prdx2−/− mice infused with saline or Ang II for 4 weeks. Scale bar, 200 µm.
c Representative immunostaining of α-SMA in cross-sectioned abdominal aortas. Nuclei were stained with hematoxylin. Scale bar, 200 µm. The boxed area
indicates the apoptotic death of VSMCs. d Representative images of H&E (left; scale bar, 200 µm) staining and immunostaining of CD31 (green) and α-SMA (red)
(right; scale bar, 50 µm) in cross-sectioned abdominal aortas. Nuclei were stained with DAPI. The boxed area shows microhemorrhage in the aneurysmal lesion.
e Extent of elastin degradation in the suprarenal artery (AU) based on Movat pentachrome-stained images of abdominal aortic cross-sections (saline groups, n
= 5–6; Ang II groups, n = 11–13). Data are presented as the mean ± SEM (two‐tailed Student’s t-test). f Immunoblotting analysis of VE-cadherin, VEGFR2, and
PRDX2 in aneurysmal aortas from Prdx2+/+ and Prdx2−/− mice infused with Ang II for 4 weeks. β-actin was used as a loading control. g AAA classiﬁcation (%) of
Prdx2+/+ (n = 25) and Prdx2−/− (n = 28) mice infused with Ang II for 4 weeks according to a scale from 0 (no aneurysm) to 4 (multiple aneurysms with thrombi).
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lesion was elevated in Prdx2−/− mice infused with Ang II
compared with that in controls (Fig. 4c and Supplementary
Fig. 3b). Moreover, α-SMA immunostaining demonstrated
that AAA lesions from Prdx2−/− mice infused with Ang II
contained a larger area of apoptotic VSMC death than
those from controls (Fig. 4c and Supplementary Fig. 3c).
With the increase in intramural thrombi, as shown in
Fig. 3c, the loss of PRDX2 locally caused an increase in
microhemorrhage in aneurysmal lesions (Fig. 4d). After
performing 2D gel electrophoresis of proteins from aortas
of Prdx2+/+ and Prdx2−/− mice infused with Ang II, we
identiﬁed 37 increased spots and 23 decreased spots with
differences of at least twofold between the two groups
using MALDI-TOF analysis (Supplementary Fig. 4a, b),
which revealed that albumin precursor levels were signiﬁcantly increased in AAA from Prdx2−/− mice infused
with Ang II compared with those from controls (Supplementary Table 1). The increase in angiogenic ECs in AAA
from Prdx2−/− mice infused with Ang II was conﬁrmed by
immunostaining for CD31 in aneurysmal lesions (Fig. 4d)
and by immunoblotting of VEGFR2 in aneurysmal aortas
(Fig. 4f). However, coimmunostaining for CD31 and αSMA in aneurysmal lesions revealed that the excess
angiogenic ECs were not covered by VSMCs (Fig. 4d). In
addition, the levels of VE-cadherin, which contributes to
the integrity of EC-EC junctions, were reduced in the AAA
of Prdx2−/− mice infused with Ang II compared with
those of controls (Fig. 4f). According to macroscopic
images and histological analysis, we classiﬁed AAA from
Prdx2+/+ (n = 25) and Prdx2−/− (n = 28) mice infused
with Ang II. In all stages (except stage 0), the loss of
PRDX2 caused an increase in the incidence of AAA in
mice infused with Ang II (Fig. 4g). These results demonstrated that the loss of PRDX2 was crucially involved in
the expansion and vulnerability of aneurysmal aortas.
Loss of PRDX2 increases the activity of MMPs and
oxidative stress in Ang II-induced AAA

MMP activity is closely associated with vascular remodeling and changes in the structural integrity of aortas in
Ang II-induced AAA formation4. Thus, we measured
MMP activity in aneurysmal aortic lesions using in situ
zymography, which revealed an increase in ﬂuorescence
intensity in Prdx2−/− mice infused with Ang II versus that
in Prdx2+/+ mice (Fig. 5a, b and Supplementary Fig. 5a).
AAA from Prdx2−/− mice infused with Ang II showed an
increase in MMP2 levels but not MMP9 levels compared
with those from controls according to immunoblotting
(Fig. 5c, d). Extracellular matrix components, including
ﬁbronectin and collagen IV, were more abundant in
aneurysmal lesions from Prdx2−/− mice infused with Ang
II than in those from controls (Fig. 5c, e), suggesting that
there was an increase in vascular remodeling caused by
the loss of PRDX2. By using a proteomics approach, it was
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shown that the levels of heat shock proteins (HSPs),
including HSP90, HSP70, and HSP60, were also signiﬁcantly increased in aneurysmal aortas from Prdx2−/−
mice compared with those from controls (Supplementary
Table 1), indicating that the loss of PRDX2 induced
stressful conditions, including aortic tissue wounding and
remodeling. These data suggested that the loss of PRDX2
accelerated the structural damage of aortas in mice after
the administration of Ang II, leading to dilatation and
structural deterioration of the aortas.
ROS have been considered a crucial stimulator for the
activation of MMPs30–32. To evaluate oxidative stress in
aneurysmal tissues from Prdx2+/+ and Prdx2−/− mice
infused with Ang II, we detected superoxide and hydrogen
peroxide using DHE and DCF-DA staining, respectively.
DHE staining revealed increased superoxide levels in
aneurysmal aorta lesions in Prdx2−/− mice infused with
Ang II compared with those in controls (Fig. 5f), but we
failed to detect the levels of hydrogen peroxide in the
lesions (data not shown). Therefore, we tried to measure
other oxidative stress indicators, such as the levels of
4-HNE and 8-OHG33,34. The levels of 4-HNE were
increased in AAA from the Ang II-infused groups compared with those in normal aortas from the saline groups
(Fig. 5g). Moreover, AAA from Ang II-infused Prdx2−/−
mice showed signiﬁcantly higher levels of 4-HNE than
AAA from Ang II-infused Prdx2+/+ mice (Fig. 5g and
Supplementary Fig. 5b). Moreover, immunostaining of
4-HNE and 8-OHG revealed that the loss of PRDX2
augmented oxidative stress during the development of
AAA (Fig. 5h). An increase in the level of succinate
dehydrogenase complex subunit A, which is involved in
ROS formation35, also indicated the increase in ROS in
aortas after the loss of PRDX2 (Supplementary Table 1).
Taken together, the results indicated that the loss of
PRDX2 in mice augmented the oxidative stress level in
aneurysmal lesions induced by Ang II infusion.
PRDX2 prevents inﬂammation in aneurysmal aortic lesions

Next, we tested whether the loss of PRDX2 regulates
inﬂammation during the pathogenesis of AAA. Our previous study showed that PRDX2 deﬁciency in ApoE−/−
mice induced the expression of CAMs such as intercellular adhesion molecule-1 (ICAM-1) and vascular
CAM-1 (VCAM-1) during the development of atherosclerosis25. Therefore, we ﬁrst veriﬁed the levels of ICAM1 and VCAM-1 in the aortas from Prdx2+/+ and Prdx2−/−
mice infused with saline or Ang II. ICAM-1 levels were
more highly increased in the aortas from Prdx2−/− mice
infused with Ang II than those in aortas from controls
(Fig. 6a, b). VCAM-1 expression showed a higher increase
with the loss of PRDX2 expression in Ang II-infused mice
than in controls, but this was not signiﬁcant (Fig. 6a, c).
Consistent with the increase in CAMs, the levels of CD45,
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(see ﬁgure on previous page)
Fig. 5 Deﬁciency of PRDX2 augments the activity of MMPs and oxidative stress in Ang II-induced AAA. Analysis of abdominal aortas from
Prdx2+/+ and Prdx2−/− mice infused with saline or Ang II for 4 weeks. a Representative in situ zymography images and b quantiﬁcation using crosssectioned abdominal aortas (saline groups, n = 3; Ang II groups, n = 5–6). Scale bar, 50 µm. Data are presented as the mean ± SEM (two‐tailed
Student’s t test). c Immunoblotting analysis of MMP2, MMP9, ﬁbronectin, collagen IV, and PRDX2 in aortas from Prdx2+/+ and Prdx2−/− mice infused
with saline or Ang II for 4 weeks. β-actin was used as a loading control. d Quantiﬁcation of MMP2 and e ﬁbronectin in Fig 5c. Data are presented as
the mean ± SEM (two‐tailed Student’s t test). f Representative confocal images of DHE staining in abdominal aortic cross-sections. Scale bar, 50 µm.
g Immunoblotting analysis of 4-HNE in aortas from Prdx2+/+ and Prdx2−/− mice infused with saline or Ang II for 4 weeks. β-actin was used as a
loading control. h Representative immunostaining images of 4-HNE (left) and 8-OHG (right) in abdominal aortic cross-sections. Low magniﬁcation
images (scale bar, 200 µm) and higher magniﬁcation of the boxed area (scale bar, 100 µm). Nuclei were stained with DAPI.

which serves as a marker of immune cells, were markedly
increased in AAA from Prdx2−/− mice infused with Ang II
compared with those in AAA from the controls (Fig. 6a,
d). Moreover, we examined the extent of immune cell
inﬁltration in the aneurysmal aortic lesions using CD45
immunostaining and found that it was signiﬁcantly
increased in Prdx2−/− mice infused with Ang II versus that
in Prdx2+/+ mice (Fig. 6e, f). MOMA2 immunostaining
revealed that most CD45-positive cells in aneurysmal
lesions were macrophages (Fig. 6g). Interestingly, PRDX2
deﬁciency systemically induced inﬂammation, which was
in line with the increase in IL-1β and IL-6 levels in the
plasma of Prdx2−/− mice infused with Ang II versus those
in Prdx2+/+ mice (Fig. 6h, i). In the proteomic analysis, an
increase in inﬂammation-related proteins, including leukotriene A-4 hydrolase, H-2 class I histocompatibility
antigen, and TLA(B) alpha chain-like, was also revealed in
Prdx2−/− mice infused with Ang II (Supplementary
Table 1). These results demonstrated that PRDX2 deﬁciency accelerated inﬂammation in ECs and immune cells
during the progression of AAA.

Discussion
Our results demonstrate the suppressive effects of
PRDX2 on the progression of AAA via the inhibition of
structural damage, oxidative stress, and inﬂammatory
responses in AAA lesions. We characterized four ways in
which PRDX2 ameliorates AAA progression (Fig. 7). First,
the expression of PRDX2 is markedly increased in the
aneurysmal aortas from both human patients and the Ang
II-induced mouse model versus that in aortas from normal controls. Second, PRDX2 prevents the Ang IIinduced structural deterioration of aortas, including
elastin degradation and aortic dilatation. Third, PRDX2
alleviates the activation of MMPs and reduces oxidative
stress in Ang II-induced AAA formation. Finally, the antiinﬂammatory properties of PRDX2 inhibit the expression
of CAMs and the accumulation of CD45-positive immune
cells in AAA. Therefore, we proposed the inhibitory role
of PRDX2 in AAA progression and other vascular diseases
involving oxidative stress and inﬂammation.
A previous study reported increased levels of PRDX2 in
ruptured aortic aneurysm tissue versus those in
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology

nonruptured aortic aneurysm tissue27. In this study, we
demonstrated an increase in PRDX2 levels in the
abdominal aortas of patients with AAA versus that in
healthy donors. Moreover, aneurysmal aortas from Ang
II-infused mice also showed an increase in PRDX2 similar
to that found in human aneurysmal aortas versus that in
controls. Intraluminal and intramural thrombi of aneurysmal aortas may enhance the levels of PRDX2 because
PRDX2 is the primary antioxidant in RBCs36. Moreover,
VSMCs treated with Ang II showed a slight increase in
PRDX2 levels, which may affect the increase in PRDX2
after VSMC proliferation in Ang II-induced aneurysmal
aortas. With regard to the cellular expression of PRDX2,
we have reported that PRDX2 is expressed in vascular
cells, including ECs and VSMCs, and macrophages
derived from the peritoneal cavity and bone marrow24. As
was the case in our previous data, we conﬁrmed that
PRDX2 expression was higher in VSMCs than in ECs and
immune cells using immunostaining.
Mullen et al.37 reported that PRDX1 and PRDX2, which
do not have signal peptides, are secreted from various
cells in response to inﬂammatory stimuli through exosomal release. Martinen-Pinna et al.38 reported that PRDX1,
which is mainly released from RBCs and polymorphonuclear neutrophils localized to the luminal part of the
AAA thrombus, was increased in the serum of patients
with AAA compared with that in the serum of healthy
individuals. This result was in line with the positive correlation of the diameter of the AAA and the expansion
rate. Then, we tried to determine whether the levels of
PRDX2 in plasma are correlated with AAA progression.
Ang II-infused mice showed a greater increase in plasma
PRDX2 than saline-infused mice. However, the levels of
hemoglobin in plasma were also comparable with the
PRDX2 levels, suggesting that contamination by RBC
lysates may play a role in the increase in plasma PRDX2.
Therefore, the increase in plasma PRDX2 could be
meaningful as a biomarker for the determination of AAA
formation or severity if luminal thrombi and RBC lysis are
involved in the pathological process of AAA.
ROS are locally increased in AAA and contribute to the
pathogenesis of aortic aneurysms in both human and
animal models5,7,39. ROS production in the vasculature
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Fig. 6 Loss of PRDX2 exacerbates inﬂammation in aneurysmal lesions. Analysis of abdominal aortas from Prdx2+/+ and Prdx2−/− mice infused
with saline or Ang II for 4 weeks. a Immunoblotting analysis of ICAM-1, VCAM-1, CD45, and PRDX2 in aortas from Prdx2+/+ and Prdx2−/− mice infused
with saline or Ang II for 4 weeks. β-actin was used as a loading control. b Quantiﬁcation of ICAM-1, c VCAM-1, and d CD45 in Fig. 6a. Data are
presented as the mean ± SEM (two‐tailed Student’s t test). e Representative immunostaining images showing the accumulation of immune cells in
aneurysmal lesions. Cross-sectional images of CD45 immunostaining (top; scale bar, 200 µm) and higher magniﬁcation of the boxed area (bottom;
scale bar, 100 µm). f Quantiﬁcation of CD45-positive cells using images of abdominal aortic cross-sections (saline groups, n = 3; Ang II groups, n = 5).
Data are presented as the mean ± SEM (two‐tailed Student’s t test). g Representative confocal images of immune cells (CD45) and macrophages
(MOMA2) in aneurysmal aortas. Scale bar, 50 µm. h The levels of IL-1β and i IL-6 in plasma from Prdx2+/+ and Prdx2−/− mice infused with saline or
Ang II for 4 weeks. Data are presented as the mean ± SEM (two‐tailed Student’s t test).

has been associated with inﬂammation and the structural
integrity of aortas. Because PRDX2 is a cellular peroxidase
that removes intracellular hydrogen peroxides19, we
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology

attempted to show the levels of hydrogen peroxides in
AAA lesions but failed because of technical issues.
However, we conﬁrmed the increase in oxidative stress in
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Fig. 7 PRDX2 prevents structural damage, oxidative stress, and
inﬂammation during the progression of AAA. The levels of PRDX2
are augmented in aneurysmal aortas and participate in ameliorating
the structural deterioration of aortas, ROS-mediated oxidative stress,
and inﬂammatory responses induced by Ang II administration.

AAA lesions from PRDX2-deﬁcient mice by DHE staining, 4-HNE and 8-OHG immunostaining, and 4-HNE
immunoblotting analysis. Inﬁltrating inﬂammatory cells
in the vasculature produce ROS and proinﬂammatory
cytokines, leading to the production of ROS by
VSMCs40,41. Moreover, elevated levels of ROS promote
aortic dilatation and rupture through the MMP-mediated
degradation of extracellular matrix and apoptosis of
VSMCs40–43. Using ultrasound imaging and histological
analysis, we demonstrated that the loss of PRDX2 induced
an increase in AAA incidence along with aortic dilatation
and the structural warping of aortas following an increase
in the inﬁltration of inﬂammatory cells into lesions and
MMP activation. Because macrophage-derived MMP9
and mesenchymal cell-derived MMP2 are both important
for the development of aortic aneurysms44, we tested the
levels of MMP2 and MMP9 in AAA from Prdx2+/+ and
Prdx2−/− mice infused with saline or Ang II. Immunoblotting analysis revealed an increase in MMP2 levels in
AAA from Ang II-infused Prdx2−/− mice, revealing that
VSMC-derived MMP2 may be critical for MMP-mediated
extracellular degradation in PRDX2-deﬁcient mice.
Moreover, the inﬁltration of immune cells induces
damage to aortic tissues through the release of proinﬂammatory cytokines, including IL-1β and IL-6, which
promote the apoptotic death of VSMCs and aortic dilatation45,46. In this study, we identiﬁed that the levels of IL1β and IL-6 in plasma from Prdx2−/− mice infused with
Ang II were increased compared with those in plasma
from control mice. However, tumor necrosis factor-α was
not detectable in plasma from all groups, and the levels of
monocyte chemoattractant protein-1 were comparable in
plasma from Prdx2+/+ and Prdx2−/− mice infused with
Ang II (data not shown).
PRDX2 has been considered a regulator of cellular
signaling via its control of endogenous hydrogen
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peroxides produced by various stimuli, including PDGF26.
PDGF, which induces the generation of hydrogen peroxides for PDGF receptor signal transduction, is a potent
growth factor that leads to the proliferation and migration
of VSMCs47. Choi et al.26 reported that the loss of PRDX2
caused the elevation of endogenous hydrogen peroxides,
leading to the proliferation and migration of VSMCs
through the strengthening of PDGF receptor signaling.
Ang II has multiple physiological effects, including the
regulation of cell proliferation and migration via the
regulation of various growth factors such as PDGF. VSMC
proliferation and migration are among the features of the
pathophysiological process of AAA formation48. Loss of
PRDX2 induced the proliferation and migration of
VSMCs during the development of AAA, leading to an
increase in the maximum aortic diameter. We veriﬁed
that multiple treatments rather than the single treatment
of VSMCs with Ang II ampliﬁed proliferation, which
likely occurred via PDGF (data not shown). However, it
must be conﬁrmed whether the loss of PRDX2 in VSMCs
accelerates proliferation and migration caused by treatment with Ang II. Moreover, Ang II modulates VEGFdriven angiogenesis in a speciﬁc manner via type 1 and
type 2 receptors. In this study, we provided evidence that
the loss of PRDX2 was associated with the formation of
immature neovessels in AAA lesions. Kang et al.49
reported that PRDX2 prevents the oxidative inactivation
of VEGFR2 in ECs, which partly disagrees with our data.
Ang II-induced angiogenesis could be mediated by multiple factors, including ROS and angiopoietin-250. Additionally, the use of different disease models might explain
the discrepancy between the two studies. Finally, VSMC
proliferation and migration may lead to the expansion of
aneurysmal aortas and increases in the apoptotic death of
VSMCs due to immature angiogenesis, oxidative stress
and inﬂammation, leading to AAA progression and
structural vulnerability in aortas in PRDX2-deﬁcient mice.
In summary, the loss of PRDX2 accelerated the progression of AAA pathophysiology through an increase in
inﬂammatory responses and structural damage to the
aorta. Although there is a need to examine the potential
therapeutic role of PRDX2 in AAA, our data support the
importance of PRDX2 in the development of aneurysmal
diseases. Moreover, the increased levels of PRDX2 in
human aneurysmal tissues or plasma may provide an
approach for developing a potential biomarker to track
the pathological development of AAA.
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